全文获取类型
收费全文 | 264篇 |
免费 | 18篇 |
出版年
2022年 | 2篇 |
2021年 | 3篇 |
2019年 | 2篇 |
2016年 | 5篇 |
2015年 | 4篇 |
2014年 | 13篇 |
2013年 | 7篇 |
2012年 | 19篇 |
2011年 | 16篇 |
2010年 | 16篇 |
2009年 | 13篇 |
2008年 | 10篇 |
2007年 | 13篇 |
2006年 | 13篇 |
2005年 | 11篇 |
2004年 | 8篇 |
2003年 | 7篇 |
2002年 | 4篇 |
2001年 | 12篇 |
2000年 | 9篇 |
1999年 | 3篇 |
1998年 | 2篇 |
1997年 | 5篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1987年 | 4篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1970年 | 2篇 |
1964年 | 3篇 |
1962年 | 2篇 |
1959年 | 2篇 |
1957年 | 2篇 |
1953年 | 2篇 |
1949年 | 2篇 |
1945年 | 2篇 |
1929年 | 1篇 |
1928年 | 1篇 |
1927年 | 1篇 |
1925年 | 1篇 |
排序方式: 共有282条查询结果,搜索用时 15 毫秒
61.
62.
A DNA primer/probe system for the rapid and sensitive detection of Mycobacterium tuberculosis-complex pathogens 总被引:1,自引:1,他引:0
Nicola T. Ralphs S. Garrett R. Morse J.B. Cookson P.W. Andrew G.J. Boulnois 《Journal of applied microbiology》1991,70(3):221-226
A 1·5 kb Eco RI– Bam HI restriction fragment from Mycobacterium tuberculosis was found to hybridize specifically with genomic DNA from M. tuberculosis -complex organisms. Primers were designed from the terminal sequences of this fragment and used to amplify uniquely M. tuberculosis -group DNA in a polymerase chain reaction. It is suggested that a combination of these primers and probe will prove a useful tool for the early diagnosis of tuberculous infections. 相似文献
63.
64.
65.
Enterococci as emerging pathogens of humans 总被引:6,自引:2,他引:4
66.
Mutations in the gene encoding LRRK2 (leucine-rich repeat kinase 2) were first identified in 2004 and have since been shown to be the single most common cause of inherited Parkinson’s disease. The protein is a large GTP-regulated serine/threonine kinase that additionally contains several protein–protein interaction domains. In the present review, we discuss three important, but unresolved, questions concerning LRRK2. We first ask: what is the normal function of LRRK2? Related to this, we discuss the evidence of LRRK2 activity as a GTPase and as a kinase and the available data on protein–protein interactions. Next we raise the question of how mutations affect LRRK2 function, focusing on some slightly controversial results related to the kinase activity of the protein in a variety of in vitro systems. Finally, we discuss what the possible mechanisms are for LRRK2-mediated neurotoxicity, in the context of known activities of the protein. 相似文献
67.
68.
69.
van de Leemput J Chandran J Knight MA Holtzclaw LA Scholz S Cookson MR Houlden H Gwinn-Hardy K Fung HC Lin X Hernandez D Simon-Sanchez J Wood NW Giunti P Rafferty I Hardy J Storey E Gardner RJ Forrest SM Fisher EM Russell JT Cai H Singleton AB 《PLoS genetics》2007,3(6):e108
We observed a severe autosomal recessive movement disorder in mice used within our laboratory. We pursued a series of experiments to define the genetic lesion underlying this disorder and to identify a cognate disease in humans with mutation at the same locus. Through linkage and sequence analysis we show here that this disorder is caused by a homozygous in-frame 18-bp deletion in Itpr1 (Itpr1Δ18/Δ18), encoding inositol 1,4,5-triphosphate receptor 1. A previously reported spontaneous Itpr1 mutation in mice causes a phenotype identical to that observed here. In both models in-frame deletion within Itpr1 leads to a decrease in the normally high level of Itpr1 expression in cerebellar Purkinje cells. Spinocerebellar ataxia 15 (SCA15), a human autosomal dominant disorder, maps to the genomic region containing ITPR1; however, to date no causal mutations had been identified. Because ataxia is a prominent feature in Itpr1 mutant mice, we performed a series of experiments to test the hypothesis that mutation at ITPR1 may be the cause of SCA15. We show here that heterozygous deletion of the 5′ part of the ITPR1 gene, encompassing exons 1–10, 1–40, and 1–44 in three studied families, underlies SCA15 in humans. 相似文献
70.
Androgen deprivation therapy (ADT) is part of standard therapy for locally advanced or metastatic prostate cancer and is frequently used in men with a rising prostate-specific antigen following radical prostatectomy or radiation therapy. In some men, ADT may be administered for years or even decades. The intended therapeutic effect of ADT is testosterone deficiency. Because estrogen is a normal metabolite of testosterone, ADT also results in estrogen deficiency. ADT has a variety of adverse effects, many of which are primarily related to estrogen deficiency. Bone mineral density may decrease by 4% to 13% per year in men receiving ADT. The fracture rate for patients on ADT averages 5% to 8% per year of therapy. Hot flashes, gynecomastia, and breast tenderness are common side effects associated with ADT. In the clinic, minimum baseline testing should include weight measurement, blood pressure reading, and fasting lipid panel and serum glucose tests. Currently, there are no large outcome trials in men on ADT testing the available therapies for adverse effects. No therapies are specifically approved for treatment of adverse effects in men on ADT. Although some therapies can be used for a single indication (based upon small studies), there is currently no agent to treat the multiple estrogenic side effects of ADT. 相似文献